Abstract: Several dicyclohexylidene tetraoxanes were prepared in order to gain a further insight into structure-activity relationship of this kind of antimalarials. The tetraoxanes 2-5, obtained as a cis/trans mixture, showed pronounced antimalarial activity against Plasmodium falciparum chloroquine susceptible D6, chloroquine resistant W2 and multidrug-resistant TM91C235 (Thailand) strains. They have better than or similar activity to the corresponding desmethyl dicyclohexylidene derivatives. Two chimeric endoperoxides with superior antimalarial activity to the natural product ascaridole were also synthesized.
INTRODUCTION
Malaria affects more than 500 million people per annum, causing more than one million deaths, mostly in Africa. 1 Infants, young children and pregnant women are particularly at risk; in fact, it has been estimated that a child dies of malaria every 30 seconds. Furthermore, the disease has as an immeasurable negative impact, both personally and socioeconomically, on families and communities in endemic areas. Although malaria is treatable, increased resistance of the protozoan parasite Plasmodium falciparum to standard and affordable anti-malarial drugs, such as chloroquine (CQ), complicates the treatment of infected individuals. Peroxide antimalarials of the 1,2,4-trioxacyclohexane class (artemisinin and its derivatives) 2 and drugs of the trioxolane class 3 offer some new possibilities for treating malaria.
Compounds of another peroxide class, the 1,2,4,5-tetraoxacyclohexanes (tetraoxanes), although less investigated, also have been shown to have potent anti-# Serbian Chemical Society member.
Current address: Faculty of Chemistry, University of Belgrade, Belgrade, Serbia. ≡ Current address: College of Public Health, University of South Florida, Tampa, USA. malarial activity. 4 Subsequently, the syntheses of mixed tetraoxanes 5, 6 enabled the controlled preparation of a new generation of this promising class of antimalarials.* In addition to the steroidal tetraoxanes, a significant number of dicyclohexylidene tetraoxanes have been synthesized and their anti-malarial activity evaluated both in vitro and in vivo. 8, 9 Monoterpene ascaridole (Scheme 1), a natural bicyclic [2.2.2] endoperoxide with moderate antimalarial properties, was used as a model for the synthesis of a series of diaryl substituted ascaridole-type endoperoxides, which showed higher activity as compared to ascaridole or dihydroascaridole. 10 More recently, the syntheses of less volatile ascaridole and dihydroascaridole derivatives have been accomplished starting from perillyl and nopol derivatives. 11 Scheme 1. Here are reported the synthesis and results of anti-malarial screening of two types of anti-malarial peroxides: mixed tetraoxanes, the derivatives of 12-methyl--7,8,15,16-tetraoxadispiro[5.2.5.2]hexadecane-3-carboxylic acid, and endoperoxides, monoterpene ascaridole derivatives, bound to another anti-malarial pharmacophore, 4-amino-7-chloroquinoline. In addition, the results of in vivo screening of some mixed steroidal tetraoxanes are also discussed.
RESULTS AND DISCUSSION

Chemistry
The class of dicyclohexylidene tetraoxanes (2-5) was designed with varying substituents at the C(4") position in order to obtain further insight into the structure-activity relationship related to spiro-substituents in 1,2,4,5-tetraoxacyclohexane at C(3) and C(6). Gem-dihydroperoxide 1 was prepared from 4-methylcyclohexanone using 30 % hydrogen peroxide and HCl as a catalyst. 5a Compound 1 was isolated in 47-85 % yield and was pure enough (Scheme 2) to be directly used in the next step.** This gem-dihydroperoxide was coupled to 4-oxocyclohe-* The structure of the previously evaluated dicyclohexylidene tetraoxanes was limited by a synthetic constraint: only bis compounds could be obtained directly from the corresponding ketones. 7 ** For alternative excellent syntheses of gem-dihydroperoxides, see reference 12.
xanecarboxylate according to a previously developed procedure 5a to yield the parent mixed tetraoxane, achiral methyl 12-methyl-7,8,15,16-tetraoxadispiro[5.2.5.2]hexadecane-3-carboxylate (2; 10-35 %). Further transformations using the ester → → acid → amide sequence (Scheme 2) afforded the desired amides 4 and 5 in 59 % and 49 % yield, respectively. Ascaridole derivatives 6 and 7 synthesized earlier 11 were hydrolysed with LiOH into the corresponding acids and further coupled to N-(7-chloroquinolin-4--yl)ethane-1,2-diamine to afford the final aminoquinoline products 8 and 9, respectively (Scheme 1).
Antimalarial activity
The synthesized peroxides were screened in vitro against three Plasmodium falciparum strains: D6 (chloroquine-susceptible), W2 (chloroquine-resistant, sus-ceptible to mefloquine), and TM91C235 (Thailand), a multidrug-resistant strain, following the protocol given in the literature. 5a All the synthesized tetraoxanes exhibited interesting antimalarial activity. In accordance with previous findings, 5a the acid 3 was less active (in this particular case -practically inactive) than the methyl ester 2 and the corresponding amides 4 and 5 against all parasite strains. One of the current hypotheses regarding the mechanism of antimalarial action of peroxides is that they act in the food vacuole (FV) of P. falciparum, which has a pH around 5.5. As such, amide 5 was designed to have an N,N-dimethylamino group, expecting that protonation of the basic nitrogen would enhance the flux of the compound through the FV membrane, thereby increasing its concentration at the desired site of action. However, the in vitro antimalarial activity data for tetraoxane 5 (Table I) does not support this hypothesis, since amide 4 (which possesses only an acidic hydrogen at the nitrogen) and ester 2 exhibit very similar activity (both IC 50 and IC 90 ) against all the tested parasites. In addition, the activities of the dicyclohexylidene tetraoxanes presented in this paper are better or equivalent to similar desmethyl compounds. 6d,9 The antimalarial activity of compounds 6-9 appears to be strongly dependent on the degree of saturation: the saturated bicyclic endoperoxides (7, 9) are more potent antimalarials relative to their unsaturated counterparts (Table I) , and both unsaturated (6,8) and saturated (7,9) endoperoxides are 5-12 times more active than ascaridole and dihydroascaridole themselves. These results indicate that peroxide-aminoquinoline chimeras, in addition to the trioxaquines, 13 might represent a promising addition to the existing antimalarial arsenal.
Finally, the results of an in vivo study on the epimeric mixed steroidal tetraoxanes 10 and 11 (Table II) are presented. 5a The in vitro activity of the com-pounds differs 20-to 30-fold, with the (4"R)-epimer 10 being more active; this structure-activity relationship qualitatively holds for other epimeric pairs at the same carbon. 5 Docking calculations of 10 and 11 with heme 14 are consistent with the observation that the proximity of the heme iron to the oxygen atom of the tetraoxane moiety favours potent in vitro activity of both compounds. The more potent analogues have much lower energy minimized docked structures. In addition, preliminary metabolic stability assays and metabolite identification were performed using human and mouse liver microsomes to aid the estimation of the first-pass metabolism of the drug candidates in relevant species (Table II) . 5c It is important to note that no scission of peroxide bond was observed (the tetraoxane moiety is stable in this assay); only monohydroxylations occurred. In this assay, 5c stable compounds were defined as having half-lives > 60 min. Both compounds have similar metabolic half-lives (t 1/2 (mouse) ≅ 30 min). Hence, it would be logical that the observed difference in in vitro activity would also be seen in the in vivo efficacy test in mice. However, the collective in vivo results presented in Table II are not consistent with results from the in vitro screening and with the docking calculations: epimers 10 and 11 exert similar in vivo activity in mice, regardless of whether they were administered orally or subcutaneously (Table II) . Furthermore, at 600 mg/kg total dose p.o. and 480 mg/kg total dose s.c. of tetraoxane 10, 4/5 and 5/5 mice cured were observed and the respective survival times were 28 and 31 days. At a total dose 150 mg/kg p.o. and 120 mg/kg s.c., very similar survival times were observed.
Analogous results were also seen for epimer 11. In addition, at comparable total doses of 150 mg/kg p.o. and 120 mg/kg s.c., compounds 10 and 11 both cured more animals orally than subcutaneously. This apparent higher bioavailability by the oral route may have resulted from a lack of absorption due to s.c. depot formation: a subcutaneous sterile pocket of oil and unabsorbed test compound was commonly found in each animal. Alternatively, one of the hydroxylated metabolites formed after oral administration may be more active than the administered parent drug. For both compounds, 10 and 11, no toxic effects were observed at any tested concentration or applied protocol.
To conclude, several dicyclohexylidene tetraoxanes were prepared and tested in order to gain additional insight into the structure-activity relationship of this structural class of antimalarials. The tetraoxanes 2-5 obtained as cis/trans mixtures exerted better, or similar activity, than the corresponding desmethyl dicyclohexylidene derivatives. 6d, 9 The initial work on ascaridole-related compounds 11 enabled the synthesis of two chimeric endoperoxides with superior antimalarial activity to the natural product, ascaridole. The present results indicate that further efforts should be put into research of peroxide-aminoquinoline chimeras as potential antimalarial drug leads. Finally, the results of in vivo tests of two epimeric tetraoxanes with a steroidal carrier indicate that subcutaneous testing using an oil vehicle for these compounds may be unsuitable. 
EXPERIMENTAL
General remarks
For details, please see references 5a, 5b, 5c. ESI MS spectra of the synthesized compounds were recorded on an Agilent Technologies 6210 Time-of-Flight LC/MS instrument in the positive ion mode using CH 3 CN/H 2 O = 1/1 with 0.2 % HCOOH as the carrying solvent solution. The samples were dissolved in pure acetonitrile (HPLC grade). The selected values were as follows: capillary voltage 4 kV; gas temperature 350 °C; drying gas 12 l min -1 ; nebuliser pressure 45 psig; fragmentator voltage 70 V.
1,1-Dihydroperoxy-4-methylcyclohexane (1)
4-Methylcyclohexanone (1.1 ml, 8.9 mmol) was dissolved at r.t. in a CH 2 Cl 2 /CH 3 CN mixture (20 ml, 1:3 v/v), followed by addition of 30 % H 2 O 2 (10.4 ml, 0.1 mol) and a few drops of conc. HCl. The reaction mixture was stirred for 2 h at r.t. and then quenched with saturated NaHCO 3 and CH 2 Cl 2 . The organic layer was separated, the water layer was additionally extracted with EtOAc (3×50 ml), and the combined organic layers were dried over anhydrous MgSO 4 and evaporated to dryness. The crude product (680 mg, 47 %) was used in the following step without further purification. IR (film, cm -1 ): 3420s, 2935s, 2865s, 1712m, 1637w, 1554m, 1378m, 1357m, 1265m, 1200w, 1158m, 1104m, 1050m, 1017m, 980m, 910m, 861m cm -1 . IR (CCl 4 , cm -1 ): 3431m, 2957s, 2930s, 2865m, 1712w, 1551s, 1454m, 1384m, 1357m, 1255s, 1222s, 1162w, 1103m, 1071m, 
Methyl 12-methyl-7,8,15,16-tetraoxadispiro[5.2.5.2]hexadecane-3-carboxylate (2)
To a cooled solution (ice bath) of dihydroperoxide 1 (1.2 g, 7.4 mmol) in CH 2 Cl 2 (20 ml), methyl 4-oxocyclohexanecarboxylate was added and after stirring for 30 min at the same temperature, 1.66 ml of an ice-bath cooled H 2 SO 4 /CH 3 CN mixture (1:10, v/v) was added dropwise. After an additional 50 min stirring, the reaction mixture was worked-up in the usual manner and purified by 
12-Methyl-7,8,15,16-tetraoxadispiro[5.2.5.2]hexadecane-3-carboxylic acid (3)
Methyl ester 2 (400 mg, 1.3 mmol) was hydrolyzed at 80 °C with NaOH (72.8 mg, 1.82 mmol) in an i-PrOH/H 2 O mixture (12 ml, 3:1 v/v). After 15 min, the reaction mixture was cooled and diluted with 20 ml H 2 O and 50 ml CH 2 Cl 2 . The water layer was acidified to pH 2 with dilute HCl, and layers were separated. The water layer was further extracted with CH 2 Cl 2 (3×20 ml); the combined organic layers were washed with water and brine, dried over anh. MgSO 4 , and evaporated to dryness. Triturating with Et 2 O afforded 305 mg (80 %) of product. m.p. 134−137 °C. IR (KBr, cm -1 ): 3449m, 2948s, 2870m, 1707s, 1447m, 1324w, 1270m, 1226m, 1069m, 976m, 936m . 
General procedure for the preparation of amides
A solution of acid 3 (103 mg, 0.36 mmol) in dry CH 2 Cl 2 (20 ml), with added Et 3 N (51 µl, 0.36 mmol) and ClCO 2 Et (35 µl, 0.36 mmol) was stirred for 90 min at 0 °C. A given amount of amine was added and after 30 min stirring, the reaction mixture was warmed to r.t. After 90 min it was diluted with H 2 O, the layers were separated and the organic layer was washed with brine, dried over anh. MgSO 4 and evaporated to dryness. 12- 8, 15, (8) Employing the above procedure, compound 6 was hydrolysed and the intermediate acid 11 
N-{2-[(7-chloro-4-quinolinyl)amino]ethyl}-3-(4-isopropyl-2,3-dioxabicyclo[2.2.2]oct-1-yl)propanamide (9)
Employing the above procedure, compound 7 was hydrolysed and the intermediate acid 11 was transformed into amide 9 (32 mg, 85 %), which was then triturated with Et 2 O. Oil. 9: 1 H-NMR (200 MHz, CDCl 3 , δ, ppm): 8.45 (m, H−C(2')), 7.88 (m, H−C(5')), 7.78 (m, H−C(8')), 7.33 (m, H−C(6')), 6.65 (bs, NH−Ar), 6.45 (bs, NH−CO), 6.24 (m, H−C(3')), 3.69−3.65 (m, CONHCH 2 CH 2 NHAr), 3.39−3.37 (m, CONHCH 2 CH 2 NHAr), 2.31−2.28 (t, 2H, J = 9.0 Hz), 1.94−1.88 (m, 4H), 1.84−1.78 (m, 2H), 1.67−1.57 (m, 5H), 0.86 (d, 6H, J = 7.0 Hz). 13 
In vitro antimalarial activity
The in vitro antimalarial drug susceptibility screen was a modification of the procedures first published by Desjardins et al., 15 with modifications developed by Milhous et al., 16 with the details given in ref. 4c.
In vivo antimalarial activity
The P. berghei mouse efficacy tests were conducted using a modified version of the Thompson test. On day 0, each mouse was inoculated intraperitoneally with 0.1 ml, 1.0×10 6 P. berghei P-line infected red blood cells from donor mice. The test drugs at 10, 20, and 80 mg/kg were suspended or dissolved in sesame oil and administered s.c. beginning on day 3 post-infection. Drug administrations were performed twice per day at 12 hours intervals for 3 days. The dose levels are given in Table II . Cure was defined as survival until day 31 post-treatment. Untreated control mice typically died on day 7−9 post-infection.
